Coherus BioSciences, Inc. has announced a clinical collaboration with STORM Therapeutics, Ltd. to evaluate the safety and efficacy of a new drug combination in a Phase 1b/2 study. The study will assess STC-15, a METTL3 inhibitor, in combination with LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor. This trial targets several types of cancer, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, and endometrial cancer. The Phase 2 portion of the study is set to evaluate expansion cohorts involving up to 188 patients in the United States. Under the agreement, Coherus will supply LOQTORZI, while STORM will serve as the trial sponsor. Both companies retain all commercial rights to their respective compounds.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。